DDInter1533 DDInter1376
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Promethazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propiomazine
Promethazine {u} (Compound) resembles {v} (Compound) Chlorprothixene
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Promethazine {u} (Compound) binds {v} (Gene) CALM3
Promethazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Promethazine {u} (Compound) causes {v} (Side Effect) Decreased appetite
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Promethazine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Promethazine (Compound) resembles Ethopropazine (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Promethazine (Compound) resembles Chlorprothixene (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Promethazine (Compound) binds CALM3 (Gene)
Promethazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Promethazine (Compound) causes Decreased appetite (Side Effect)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Promethazine may lead to a major life threatening interaction when taken with Toremifene